Cerevel Therapeutics Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cerevel Therapeutics Holdings generated cash of -$342,301,000, which is less than the previous year. Cash used in financing activities reached the amount of $548,616,000 last year. Net change in cash is therefore $98,935,000.
Cash Flow
| 2012 | -25.31M | -36.54M | 61.27M |
|---|---|---|---|
| 2013 | -27.85M | 16.04M | -180K |
| 2014 | -22.56M | -3.58M | 20.59M |
| 2015 | -23.21M | 24.06M | 2.72M |
| 2019 | -70.72M | -1.09M | 60.05M |
| 2020 | -117.80M | -18.89M | 440.83M |
| 2021 | -178.54M | -435.66M | 423.60M |
| 2022 | -293.18M | -388.83M | 623.19M |
| 2023 | -342.30M | 73.72M | 548.61M |
CERE Cash Flow Statement (2012 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 892.03M | 197.21M | 387.82M | 83.68M | 95.44M | 3.42M | 8.88M | 21.06M | 21.91M |
Operating activities | |||||||||
Net income | -432.84M | -351.51M | -225.33M | -152.14M | -128.38M | -28.15M | -29.32M | -32.51M | -29.41M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 5.62M | 4.90M | 2.73M | 397K | 177K | 657K | 1.51M | 1.91M | 2.05M |
Stock-based compensation expense | 69.41M | 38.78M | 23.94M | 10.52M | 8.31M | 2.26M | 3.06M | 3.31M | 1.90M |
| Deferred income tax benefit | 69.41M | 38.78M | 23.94M | 10.52M | 8.31M | 2.26M | 3.06M | 3.31M | 1.90M |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | -208K | 589K | -195K | 527K |
Inventories | 0 | 0 | 0 | 0 | 0 | 65K | -61K | 679K | -841K |
Accounts payable | 2.03M | -763K | 7.27M | 1.41M | 607K | 892K | 390K | -1.51M | -1.82M |
Cash generated by operating activities | -342.30M | -293.18M | -178.54M | -117.80M | -70.72M | -23.21M | -22.56M | -27.85M | -25.31M |
Investing activities | |||||||||
Purchases Of Investments | -865.27M | -887.73M | -425.15M | 0 | 0 | -720K | -33.08M | -15.94M | -39.27M |
Investments In Property Plant And Equipment | -3.80M | -3.95M | -10.50M | -18.89M | -1.09M | -387K | -1.01M | -892K | -1.26M |
Acquisitions Net | -77.53K | 384.88K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 73.72M | -388.83M | -435.66M | -18.89M | -1.09M | 24.06M | -3.58M | 16.04M | -36.54M |
Financing activities | |||||||||
Common Stock Issued | 517.50M | 251.31M | 328.25M | 5.53M | 60.05M | 2.79M | 20.75M | 60K | 538K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -21.06M |
Repayments of term debt | 0 | 0 | -31.25M | 0 | 0 | 0 | -159K | -240K | -6.92M |
Cash used in financing activities | 548.61M | 623.19M | 423.60M | 440.83M | 60.05M | 2.72M | 20.59M | -180K | 61.27M |
Net Change In Cash | 98.93M | -58.83M | -190.60M | 304.14M | -11.76M | 4.67M | -5.45M | -12.18M | -842K |
Cash at end of period | 990.96M | 138.38M | 197.21M | 387.82M | 83.68M | 8.09M | 3.42M | 8.88M | 21.06M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |